COGLAMUNE

Not authorised

- Clostridium perfringens, type A, alpha toxoid
- Clostridium perfringens, type D, epsilon toxoid
- Clostridium perfringens, type C, beta toxoid

Product identification

Medicine name:
COGLAMUNE

Active substance:
Clostridium perfringens, type A, alpha toxoid
Clostridium perfringens, type D, epsilon toxoid
Clostridium perfringens, type C, beta toxoid

Target species:
Cattle
Rabbit (for reproduction)
Pig (for reproduction)
Pig (for fattening)
Rabbit
Sheep
Goat

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Clostridium perfringens, type A, alpha toxoid
2.00 international unit(s) / 2.00 millilitre(s)

Clostridium perfringens, type D, epsilon toxoid
5.00 international unit(s) / 2.00 millilitre(s)

Clostridium perfringens, type C, beta toxoid
10.00 international unit(s) / 2.00 millilitre(s)

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Cattle**
  - All relevant tissues. 0 day
- **Rabbit (for reproduction)**
  - All relevant tissues. 0 day
- **Pig (for fattening)**
  - All relevant tissues. 0 day
- **Rabbit**
  - All relevant tissues. 0 day
- **Sheep**
  - All relevant tissues. 0 day
- **Goat**

- All relevant tissues. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI02AB01
QI03AB
QI04AB01
QI08AB
QI09AB12

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Surrendered

Authorised in:
France

Package description:
Available only in French
Available only in French

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:
Ceva Sante Animale

Marketing authorisation date:
27/05/1983

Manufacturing sites for batch release:
CZ Vaccines S.A.U.

Responsible authority:
French Agency For Food, Environmental And Occupational Health & Safety

Authorisation number:
FR/V/3350147 3/1983

Date of authorisation status change:
15/05/2024

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.